{
    "id": "9134415",
    "text": "Toralizumab (IDEC 131) was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody- mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstr\u00f6m's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).Statement On A Nonproprietary Name Adopted By The USAN Council - Toralizumab, American Medical Association. In Phase II clinical trials regarding multiple sclerosis and Crohn's disease, thromboembolisms occurred in at least three patients. A causal connection could not be proven, but since the same adverse effects were seen in trials with a similar antibody (hu5C8), the trials were halted. The drug was developed by IDEC Pharmaceuticals Corporation. == References == Category:Monoclonal antibodies ",
    "title": "Toralizumab"
}